Tim Forshew

Neogen Europe (United Kingdom) — United Kingdom

Medicine · Health Sciences

31h-index9.2kcitations139works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(40), Cancer Genomics and Diagnostics(31), Cancer, Hypoxia, and Metabolism(28), Ubiquitin and proteasome pathways(26), ATP Synthase and ATPases Research(26)

Publications136 total

Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types
The Journal of Liquid Biopsy·2025Open Access
Performance Characterisation of a Novel Whole Genome Sequencing Informed MRD Assay
The Journal of Liquid Biopsy·2025Open Access
Analytical validation and clinical performance of a plasma-based CGP assay, NEO | PanTracer LBx.
Journal of Clinical Oncology·2025
Abstract 4090: Analytical validation of PanTracer LBx performance, a comprehensive pan-solid tumor liquid biopsy assay
Cancer Research·2025
Abstract 3384: Evaluation of a tumor informed MRD assay with contrived breast cancer samples
Cancer Research·2023· 2 cited
Supplementary Figure 4 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Table 3 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Table 2 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Figure 9 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Figure 2 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Data from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Table 2 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Table 4 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Figure 7 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Figure 6 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Table 1 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Table 4 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Figure 6 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Figure 3 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
Supplementary Figure 1 from Targeted Therapy for <i>BRAF<sup>V600E</sup></i> Malignant Astrocytoma
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Nitzan Rosenfeld(15), Denise Sheer(11), Davina Gale(10), Andrew Lawson(10), Alice Gutteridge(9), Ruth Tatevossian(8), Thomas S. Jacques(8), Muhammed Murtaza(7), Carlos Caldas(6), Karen Howarth(6), Vincent Plagnol(6), Dana W.Y. Tsui(5), T. Alwyn Jones(5), Francesco Marass(4), James D. Brenton(4), David W. Ellison(4), Guy Hindley(4), Giovanni Marsico(4), Sarah‐Jane Dawson(3), Suet‐Feung Chin(3)